SubHero Banner

Tecentriq® (atezolizumab) – New indication

March 8, 2019 - Genentech announced the FDA approval of Tecentriq (atezolizumab), in combination with Abraxane® (paclitaxel protein-bound), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test.

Download PDF